All patients have completed their final clinical assessment. The data are being analysed, and results will be delivered in the first quarter of 2008.
This Phase IIa trial is a double blind, placebo-controlled study exploring the safety and tolerability of PBT2, Prana’s proprietary lead compound. The trial also measured PBT2’s effects on the mechanism and progression of the disease, by investigating biomarkers of Alzheimer’s disease, as well as measures of cognition.
Geoffrey Kempler, chairman and CEO of Prana Biotechnology, said: “The completion of the Phase IIa trial for PBT2 represents a significant milestone in the development of Prana’s innovative therapeutic platform for Alzheimer’s disease, and other neurodegenerative diseases.”